Press "Enter" to skip to content

GSK’s Dovato meets primary goal in late-stage HIV study

The company’s HIV drugs division ViiV said the late stage study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults who switched to the regimen from at least a triple combination TAF-containing treatment.

Original source: https://health.economictimes.indiatimes.com/news/pharma/gsks-dovato-meets-primary-goal-in-late-stage-hiv-study/70155206?utm_source=RSS&utm_medium=ETRSS

Also Read:   Moderna, Switzerland's Lonza strike deal on potential COVID-19 vaccine